Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Five things for pharma marketers to know: Thursday, June 15, 2017
Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
Five things for pharma marketers to know: Thursday, February 2, 2017
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
Merck will evaluate Keytruda cancer combo therapy
March 31, 2015
7:00 pm
Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
23andMe will harness genetic research in new drug discovery unit
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Newly discovered ALS gene may lead to new drug targets
February 19, 2015
7:00 pm
A research collaboration between medical centers, drugmaker Biogen Idec and a biotechnology institute have identified a gene that could lead to new drug targets for sporadic amyotrophic lateral sclerosis—or Lou Gehrig’s disease.